Showing 6801-6810 of 7490 results for "".
- Radiesse Hits Double Digitshttps://practicaldermatology.com/news/radiesse-hits-double-digits/2458312/Merz Aesthetics’ flagship brand, Radiesse, turned 10 this year, and was feted in style at a throw-back Thursday media event in New York City. The party took beauty bloggers and journos back to 2007 when the first iPhone was released to the publi
- Certain Lifestyle Choices May Trump Genes When it Comes to Youthful Looking Skinhttps://practicaldermatology.com/news/certain-lifestyle-choices-may-trump-genes-when-it-comes-to-youthful-looking-skin/2458313/Nurture has a larger effect on exceptionally youthful skin appearance than nature, according to a new study by Olay done in collaboration with personal genetics company 23andMe. Specifically, sunscreen usage and
- Umbrellas Plus Sunscreen Needed to Stave Off Sunburnshttps://practicaldermatology.com/news/umbrellas-plus-sunscreen-needed-to-stave-off-sunburns/2458317/When it comes to preventing sunburns, neither beach umbrella or SPF 100 sunscreen are enough on their own, according to a new study in JAMA Dermatology that suggests both are needed for sufficient sun prote
- Non-heterosexual Black Male Teens Use Tanning Beds as Much as Caucasian Female Teenshttps://practicaldermatology.com/news/non-heterosexual-black-male-teens-use-tanning-besds-as-much-as-caucasian-female-teens/2458324/The use of indoor tanning among non-heterosexual black male teens is nearly equal to that of heterosexual white females, according to a study in JAMA Dermatology. The data comes from the 2
- Menlo Begins Enrollment for Phase 2 Studies of NK-1 for Pruritushttps://practicaldermatology.com/news/menlo-begins-enrollment-for-phase-2-studies-of-nk-1-for-pruritus/2458325/Menlo Therapeutics Inc. has initiated enrollment in two new Phase 2 trials evaluating a novel neurokinin 1 (NK-1) receptor antagonist, serlopitant, for the treatment of pruritus associated with atopic dermatitis and for the treatment of pruritus fol
- Smart Hairbrush and Overachieving Mirrors Make Waves at CES 2017https://practicaldermatology.com/news/smart-hairbrush-and-overachieving-mirrors-make-waves-at-ces-2017/2458328/Beauty is getting a whole lot smarter, and more and more companies are getting in on the game. These are among the main takeaways from the BeautyTech Summit at the annual Consumer Electronics Show (CES), taking place in Las Vegas from Jan. 5-8, 2017. This is the be-all, end-all trade show
- New Compound May Block Spread of Melanoma, Treat Sclerodermahttps://practicaldermatology.com/news/new-compound-may-block-spread-of-melanoma-treat-scleroderma/2458329/A chemical compound, and potential new drug, may reduce the spread of melanoma cells by up to 90 percent, report researchers from Michigan State University in East Lansing. The man-made, small-molecule drug compound goes after a gene’s ability to produce RNA molecules and certain pr
- Study Examines Diversity in Dermatologic Clinical Trialshttps://practicaldermatology.com/news/study-examines-diversity-in-dermatologic-clinical-trials/2458332/Dermatologic clinical trials within the United States reflect the growing diversity of the US population, but reporting of both sex and racial/ethnic diversity of research cohorts is still lacking, especially among studies conducted outside of the United States, according to a new report publishe
- Revance Starts Phase III Program for Injectable Toxin in Frown Lineshttps://practicaldermatology.com/news/revance-starts-phase-iii-program-for-injectable-toxin-in-frown-lines/2458330/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials follo
- Skin Cancer Foundation: Bill Ridenour Is New Senior Director of Partnership Developmenthttps://practicaldermatology.com/news/skin-cancer-foundation/2458333/The Skin Cancer Foundation has appointmented Bill Ridenour to the role of senior director of partnership development. Ridenour’s career has spanned over 30 years in the advertising industry and this new position marks a switch to the nonprofit sector. Prior to his appointment, Ridenour